Pharmacometric Evaluation of Sulfadoxine-Pyrimethamine-Amodiaquine and Dihydroartemisinin-Piperaquine Seasonal Malaria Chemoprevention in Northern Uganda
Clinical Infectious Diseases · 13.11.2025
DOI: 10.1093/cid/ciaf615 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 13.11.2025. Verfasst von Craig Bonnington und 20 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, UK. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bill & Melinda Gates Foundation, GiveWell, Wellcome Trust.
Abstract (Originalsprache)
Background
Seasonal malaria chemoprevention (SMC) using monthly sulfadoxine-pyrimethamine-amodiaquine (SPAQ) is being deployed in East Africa, where antimalarial drug-resistance levels are high. Dihydroartemisinin-piperaquine (DP) is a potential alternative.
Methods
A prospective 28-day pharmacometric assessment of SMC was conducted in Karamoja, northern Uganda. In 2 villages children received SPAQ and in a third were randomized to DP versus no SMC. The primary outcome was malaria infection defined by capillary blood sample quantitative PCR (qPCR) positivity on day 28, or presentation with fever and slide or rapid test positivity after day 2.
Results
Baseline qPCR malaria parasitemia prevalence among 1250 enrolled children was 46% (575/1250); Plasmodium falciparum 85%, other malarias (mainly Plasmodium ovale) 25%. Breakthrough parasitemias occurred in 7% (33/496) of DP, 31% (158/504) of SPAQ, and 39% (98/250) of no drug recipients. Clinical malaria (all P falciparum) developed in 17% of no drug (42/250; 1 severe), 8% of SPAQ (38/504; 2 severe), and 2% of DP (13/496) recipients. Adjusted protective efficacies against all malaria parasitemia, P falciparum parasitemia, and clinical malaria for SPAQ were 56% (95% CI, 35%–70%), 46% (11%–68%), and 60% (27%–78%) and for DP were 84% (77%–89%), 86% (75%–92%), and 86% (74%–92%), respectively. Some asymptomatic P falciparum infections were not cleared by SPAQ. All 260 P falciparum isolates genotyped were PfCRT K76 (haplotype CVMNK, marker of 4-aminoquinoline susceptibility); most were quintuple Pfdhfr/dhps mutants (ie, relatively sulfadoxine-pyrimethamine resistant). The chemoprevention drug exposure–response relationship was strong for desethylamodiaquine, but weak for sulfadoxine.
Conclusions
SPAQ SMC had low clinical and parasitological chemopreventive efficacy in northern Uganda, whereas DP was effective. Clinical Trials Registration NCT05323721.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, UK.
- Malaria Consortium, Kampala, Uganda.
- Malaria Consortium, London, United Kingdom.
- Infectious Diseases Research Collaboration, Kampala, Uganda.
- Ministry of Health, Kampala, Uganda.
- Mahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
ORCID-Profile: Craig Bonnington, Katherine Theiss-Nyland, Richard Kajubi, Joaniter Nankabirwa, Chayanin Sararat, James A Watson, Stephane Proux, Joel Tarning, James Tibenderana, Nicholas J White
Förderung
- Bill & Melinda Gates Foundation
- GiveWell
- Wellcome Trust
- Infectious Diseases Research Collaboration
- Malaria Consortium
- Gates Foundation
Zitieren
APA
Bonnington, C., Nuwa, A., Theiss-Nyland, K., Kajubi, R., Kamya, M. R., Nankabirwa, J., Ebong, C., Nabakooza, J., Opigo, J., Salandindi, D., Odongo, M., Sararat, C., Watson, J. A., Suwannasin, K., Proux, S., Koesukwiwat, U., Tarning, J., Imwong, M., Tibenderana, J., …, & White, N. J. (2025). Pharmacometric Evaluation of Sulfadoxine-Pyrimethamine-Amodiaquine and Dihydroartemisinin-Piperaquine Seasonal Malaria Chemoprevention in Northern Uganda. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf615
Vancouver
Bonnington C, Nuwa A, Theiss-Nyland K, Kajubi R, Kamya MR, Nankabirwa J, et al. Pharmacometric Evaluation of Sulfadoxine-Pyrimethamine-Amodiaquine and Dihydroartemisinin-Piperaquine Seasonal Malaria Chemoprevention in Northern Uganda. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf615
BibTeX
@article{Bonnington2025,
author = {Bonnington, Craig and Nuwa, Anthony and Theiss-Nyland, Katherine and Kajubi, Richard and Kamya, Moses R and Nankabirwa, Joaniter and Ebong, Christopher and Nabakooza, Jane and Opigo, Jimmy and Salandindi, David and Odongo, Musa and Sararat, Chayanin and Watson, James A and Suwannasin, Kanokon and Proux, Stephane and Koesukwiwat, Urairat and Tarning, Joel and Imwong, Mallika and Tibenderana, James and Nosten, Francois H and White, Nicholas J},
title = {Pharmacometric Evaluation of Sulfadoxine-Pyrimethamine-Amodiaquine and Dihydroartemisinin-Piperaquine Seasonal Malaria Chemoprevention in Northern Uganda},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciaf615}
}
EUVIMED